Last kr493.00 DKK
Change Today -5.80 / -1.16%
Volume 185.3K
GEN On Other Exchanges
As of 11:06 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

genmab a/s (GEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/15 - kr502.00
52 Week Low
05/20/14 - kr180.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENMAB A/S (GEN)

Related News

No related news articles were found.

genmab a/s (GEN) Related Businessweek News

No Related Businessweek News Found

genmab a/s (GEN) Details

Genmab A/S, a biotechnology company, develops human antibody therapeutics for the treatment of cancer in Denmark, the Netherlands, the United States, and internationally. Its product pipeline includes Ofatumumab, a human monoclonal antibody, which is in Phase IV clinical studies for the treatment of chronic lymphocytic leukemia; Phase III clinical studies to treat follicular lymphoma, diffuse large B-cell lymphoma, and pemphigus vulgaris; Phase II clinical studies for the treatment of relapsing-remitting multiple sclerosis, and Waldenstrom’s Macroglobulinemia, as well as Daratumumab, a human CD38 monoclonal antibody that is in Phase I/II clinical studies to treat multiple myeloma. The company’s product pipeline also comprises HuMax-TF-ADC, an antibody-drug conjugate (ADC), which is in Phase I clinical studies for the treatment of solid tumors; and Teprotumumab, a human antibody that is in Phase II clinical studies for the treatment of active thyroid eye disease. In addition, it has approximately ten active pre-clinical pipeline programs, including naked antibodies and bispecific antibodies developed using DuoBody technology and ADC. The company has collaborations with GlaxoSmithKline, Janssen Biotech, Inc. (Janssen), Seattle Genetics, Inc., Roche, and H. Lundbeck A/S; and technology partnerships with Medarex, Novartis, and Janssen. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

176 Employees
Last Reported Date: 11/5/14
Founded in 1999

genmab a/s (GEN) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: kr10.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr4.9M
Compensation as of Fiscal Year 2013.

genmab a/s (GEN) Key Developments

Genmab A/S Enters Commercial Duobody Technology Agreement with BioNovion in the Field of Immuno-Oncology

Genmab A/S announced it has entered a co-development and commercialization agreement with BioNovion to evaluate a number of DuoBody product candidates targeting immune checkpoints. Genmab and BioNovion will contribute panels of antibodies for the creation of bispecific antibody products using Genmab's DuoBody platform technology. If the companies jointly select a product candidate for clinical development, development costs will be shared equally, with each party retaining a 50% share of the product rights. If one of the companies decides not to move a therapeutic candidate forward, the other company is entitled to continue developing the product at predefined licensing terms. The agreement also includes terms which allow the parties to opt out of joint development at key points in each product's clinical development. This commercial agreement follows a July 2014 research collaboration between Genmab and BioNovion.

Genmab A/S Reports Sales Results for the Fourth Quarter and Full Year of 2014

Genmab A/S reported sales results for the fourth quarter and full year of 2014. The company reported net sales of Arzerra (ofatumumab) during the fourth quarter of 2014 were GBP 12.3 million (approximately DKK 116 million). Full year 2014 net sales of Arzerra totaled GBP 54.5 million (approximately DKK 503 million) worldwide, compared to GBP 74.9 million in 2013.

GlaxoSmithKline Reportedly Seeks To Sell 7.9% Stake In Genmab

GlaxoSmithKline plc (LSE:GSK) is planning to sell 7.9% stake in Genmab A/S (CPSE:GEN) to institutional investors, GlaxoSmithKline said. "Since the announcement of the sale of GSK's marketed Oncology portfolio to Novartis, GSK has considered its stake in Genmab to be a non-core asset," GlaxoSmithKline said in a statement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:DC kr493.00 DKK -5.80

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.96 EUR 0.00
Dyax Corp $15.11 USD -0.37
ImmunoGen Inc $7.60 USD -0.19
MorphoSys AG €74.66 EUR +0.153
Seattle Genetics Inc $36.25 USD -0.18
View Industry Companies

Industry Analysis


Industry Average

Valuation GEN Industry Range
Price/Earnings 83.7x
Price/Sales 29.0x
Price/Book 12.8x
Price/Cash Flow 85.0x
TEV/Sales 26.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMAB A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at